12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BA058-transdermal: Completed Phase II enrollment

Radius completed enrollment of 250 postmenopausal women with osteoporosis in a double-blind, placebo-controlled, international Phase II trial comparing 50, 100 and 150 µg BA058-TD once daily vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC) for 6 months. BA058-Injection is in Phase...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >